Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis

Open access
Gounder, Mrinal M., Lefkowitz, Robert A., Keohan, Mary Louise, D'Adamo, David R., Hameed, Meera, Antonescu, Cristina R., Singer, Samuel, Stout, Katherine, Ahn, Linda, Maki, Robert G.·2011·Clinical Cancer Research

Abstract

Background: Desmoid tumors (deep fibromatoses) are clonal connective tissue malignancies that do not metastasize, but have a significant risk of local recurrence, and are associated with morbidity and occasionally mortality. Responses of desmoid patients to sorafenib on an expanded access program led us to review our experience. Methods: After Institutional Review Board (IRB) approval, we reviewed data for 26 patients with desmoid tumors treated with sorafenib. Sorafenib was administered at 400 mg oral daily and adjusted for toxicity. Results: Sorafenib was the first-line therapy in 11/26 patients and the remaining 15/26 had received a median of 2 prior lines of therapy. Twenty-three of 26 patients had shown evidence of progressive disease by imaging, whereas 3 patients had achieved maximum benefit or toxicity with chemotherapy. Sixteen of 22 (∼70%) patients reported significant improvement of symptoms. At a median of 6 months (2–29) of treatment, the best response evaluation criteria in solid tumors (RECIST) 1.1 response included 6/24 (25%) patients with partial response (PR), 17/24 (70%) with stable disease, and 1 with progression and death. Twelve of 13 (92%) patients evaluated by MRI had > 30% decrease in T2 signal intensity, an indirect metric for increased fibrosis and loss of cellularity. Eighty percent of patients with radiological benefit had extra-abdominal desmoids. Discussion: Sorafenib is active against desmoid tumors. A prospective, randomized clinical trial of sorafenib against other active agents is warranted. Loss of MRI T2 signal may be a useful surrogate for defining responses, but requires validation by examination of tumor pathology. Clin Cancer Res; 17(12); 4082–90. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-3322

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 255

Metadata

Authors
Gounder, M. M., Lefkowitz, R. A., Keohan, M. L., D'Adamo, D. R., Hameed, M., Antonescu, C. R., Singer, S., Stout, K., Ahn, L., & Maki, R. G.
Venue
Clinical Cancer Research
Published
2011-06-15
Volume
17
Issue
12
Pages
4082-4090
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2152015156
Cited by
255
References
13
FWCI
11.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3322
The paper
Gounder, M. M., Lefkowitz, R. A., Keohan, M. L., D'Adamo, D. R., Hameed, M., Antonescu, C. R., Singer, S., Stout, K., Ahn, L., & Maki, R. G. (2011). Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3322

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.